TerminatedNot Applicable

Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation

Stopped: PI Ryan D Stevenson left Organization (Genesys) prior to Ascension acquiring record; no evidence of completion

United States3 participantsStarted 2011-03

Plain-language summary

The goal of this research is to demonstrate the use of petroleum jelly in prevention of nonscalp seborrheic dermatitis exacerbations at the first signs of a flare. In doing so, it will decrease the chronic use of topical steroids. The use of petrolatum should have favorable outcomes for patients, without the side-effects.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-75 years old who are patients of the Genesys East Flint Clinic and have been diagnosed with recurrent NSSD * Patients are to use the petrolatum treatment strictly for the initial symptoms of NSSD: Excessive flaking, and erythematous macules or papules * Patients who are able to attend the follow-up appointments for assessment * Patients are to have the doctor's confidence that that patient will correctly implement the treatment plan Exclusion Criteria: * Patients not in the 18-75 years of age range. * Patients who are receiving treatment for their seborrheic dermatitis (Scalp or nonscalp) elsewhere. * Patients who have not demonstrated recurrent NSSD. * Patients who are unable to commit to a follow-up appointments for assessment. * Patients who do not have the physician's confidence in implementing the studies treatment plan effectively. * Patient's who are unable/unwilling to have petrolatum on affected area for at least a 6 hour length of time.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Measuring the Effectiveness of Petroleum Jelly in Treating Nonscalp Seborrheic Dermatitis

Timeframe: 4 weeks

Trial details

NCT IDNCT01315951

SponsorAscension Health

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-02

View on ClinicalTrials.gov More Seborrheic Dermatitis trials